Device Trial Radar · NCT04217837
Treatment of Major Depressive Disorder in the UK Using TMS Therapy
Last checked: Nov 19, 2026Latest source record: Oct 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 2020
Primary completion
Feb 2022
Study completion Feb 2022
Sponsor
- Lead sponsor
- NeuroneticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 3, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The major objective of this observational study is to describe clinical outcomes of patients in the UK receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.
Conditions
- Major Depressive Disorder
Interventions
Transcranial Magnetic StimulatorDevice
Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Global Impression - Severity ScaleTime frame: Baseline, 6 weeks, 3, 6, 9, and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St Pancras Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.